

**Table 4 : Outcome in the second protocol with survivin-2B peptide mixed IFA**

<b>patient no.</b>	<b>dose of peptide (mg)</b>	<b>vaccination times</b>	<b>adverse event</b>	<b>Tumor marker (pre- / post-)</b>	<b>evaluation of CT image</b>	<b>DTH skin test</b>	<b>tetramer staining</b>	<b>ELISPOT assay</b>
1	1.0	4	induration	CEA (4.9ng/ml / 7.4ng/ml)	PD	+	detected	-
2	1.0	3						
3	1.0	4	induration	CA15-3 (26.8U/ml / 79.7U/ml)	PD	-	detected	-
4	1.0	4	general malaise	CEA (23.2ng/ml / 33.9ng/ml)	PD	-	detected	-
5	1.0	4	general malaise fever	ICTP (11.8ng/ml / 28.0ng/ml)	PD	-	detected	+

tumor marker : pre- : before the 1<sup>st</sup> vaccination, post : after the 4<sup>th</sup> vaccination,

evaluation of CT image : PD : progressive disease,

DTH skin test : + : positive reaction, - : negative reaction

tetramer staining : detected : an increase of twofold or more, undetected : a less than twofold increase

ELISPOT assay : + : many spots were visualized, - : spots were almost not visualized